18 Nov 2026
Clascoterone for Hair Loss: Evidence, Safety, Phase 3 Results, and Availability
Review clascoterone hair loss evidence, Phase 3 results, safety, FDA status, and availability to make informed treatment decisions. See what experts know.
Share
TL;DR
Clascoterone for hair loss is an investigational topical androgen-receptor blocker for male androgenetic alopecia. Phase 3 announcements are encouraging, but it is not FDA-approved for hair loss, has not proved superior to finasteride or minoxidil, and should not be bought from unverified sellers.
Table of Contents
- Clascoterone for Hair Loss: The Short, Straight Answer
- What Is Clascoterone, and Are Breezula and Winlevi the Same Thing?
- How Topical Androgen-Receptor Blocking Could Affect Pattern Hair Loss
- What the Clascoterone Phase 3 Trials Actually Showed
- Clascoterone vs. Finasteride vs. Minoxidil
- Clascoterone Side Effects and the Risks Still Unknown
- When Could Clascoterone for Hair Loss Become Available?
- Who Might Fit the Studied Population—and Who May Need a Different Approach?
- The Practical Questions Headlines Leave Out
- FAQ
- Stop Guessing, Start Growing
Clascoterone for Hair Loss: The Short, Straight Answer

Clascoterone is a topical androgen-receptor inhibitor being investigated for androgenetic alopecia, commonly called male pattern hair loss. It is not currently an FDA-approved hair-loss treatment.
Positive Phase 3 announcements support further review, but they do not establish universal regrowth, superiority over existing treatments or permanent results. Our view is straightforward: identify the type and cause of hair loss before deciding whether any treatment headline is relevant.
This article provides general information, not a diagnosis or personal treatment plan. Medication decisions require an appropriately qualified clinician.
TL;DR: Promising, Investigational, and Not Yet Available
Researchers have studied a 5% topical clascoterone solution in men with mild-to-moderate androgenetic alopecia. Results reported by the manufacturer were positive, including sustained efficacy with continued treatment through 12 months. Regulatory review and approval have not yet occurred.
What Is Clascoterone, and Are Breezula and Winlevi the Same Thing?
Clascoterone, also called cortexolone 17α-propionate or CB-03-01, is the active ingredient. Breezula and Winlevi use or refer to that ingredient in different products and indications.
Breezula is the development name associated with clascoterone for androgenetic alopecia. Winlevi is an approved 1% clascoterone cream for acne, not an approved scalp treatment.
Active Ingredient Versus Product and Indication
| Name | What it refers to | Formulation | Status |
|---|---|---|---|
| Clascoterone | Active ingredient | Depends on the product | Not a single interchangeable product |
| Breezula | Hair-loss development program | Investigational 5% solution | Not approved for hair loss |
| Winlevi | Acne medication | 1% cream | Approved for acne, not hair loss |
Sharing an ingredient does not make products interchangeable. Concentration, vehicle, application site, dosing, manufacturing and clinical evidence all matter.
Why “Clascoterone Cream” Is Not a Precise Hair-Loss Search
Searching for clascoterone cream can blur the distinction between an approved acne cream and an investigational scalp solution. Even a product advertised as “clascoterone 5%” may not match the formulation used in clinical trials.
We do not recommend repurposing acne cream or buying an unverified compounded product for scalp use.
How Topical Androgen-Receptor Blocking Could Affect Pattern Hair Loss

In genetically susceptible follicles, androgen signaling contributes to progressive miniaturization. Affected hairs become finer and shorter, often around the temples, frontal scalp and crown.
Clascoterone is intended to inhibit androgen signaling locally at the receptor. That differs from reducing the body’s production of dihydrotestosterone, or DHT.
Blocking the Signal Versus Reducing DHT Formation
Clascoterone is designed to block androgen activity at receptors in treated skin. Finasteride inhibits an enzyme involved in converting testosterone to DHT.
The distinction does not prove that either approach is stronger or safer for every patient. For more context on established DHT-targeting medicines, see our comparison of dutasteride versus finasteride.
Why Genetics and Hair-Loss Pattern Still Matter
Gradual recession or crown thinning may point toward androgenetic alopecia, particularly with a family history. Those clues must still be considered alongside onset, progression, health history and scalp findings.
Roots by GA is a personalized genetic hair-loss resource, not a clascoterone seller or prescriber. We use genetic context to support more informed conversations rather than trend-driven treatment decisions.
What the Clascoterone Phase 3 Trials Actually Showed
SCALP-1 and SCALP-2 enrolled a combined 1,465 men across 51 sites in the United States and Europe. Cosmo Pharmaceuticals announced positive results for clascoterone 5% topical solution, including sustained efficacy through 12 months.
These are manufacturer-announced findings. Full peer-reviewed reporting, independent analysis and regulatory assessment remain important. Our clascoterone scalp-trial update follows that distinction.
SCALP-1 and SCALP-2 at a Glance
| Feature | Reported Phase 3 program |
|---|---|
| Population | Men with mild-to-moderate androgenetic alopecia |
| Combined enrollment | 1,465 participants |
| Investigational product | Clascoterone 5% topical solution |
| Main measure | Target-area hair count |
| Longer-term finding | Sustained efficacy reported through 12 months |
| Status | Positive findings announced; approval pending |
Target-area hair count is an objective measure within a defined scalp area. It does not show how noticeable the change was for every participant.
How to Read Hair-Count and One-Year Claims
Several measures can be confused:
- Change from baseline: The difference from the group’s starting point.
- Difference versus vehicle: The treatment group’s result compared with the inactive formulation.
- Relative difference: A percentage that can look large without showing the absolute change.
- Visible improvement: Whether patients can meaningfully see the result.
Improvement without a plateau during the reported period does not mean growth will continue indefinitely. It also tells us little about what happens after treatment stops.
What Phase 3 Can and Cannot Establish
Phase 3 trials can assess efficacy and adverse events in a defined population under controlled conditions. They cannot guarantee individual results, establish benefits for every type of hair loss or prove superiority to finasteride or minoxidil without appropriate comparative trials.
Clascoterone vs. Finasteride vs. Minoxidil
| Treatment | Main target | Route | Status for hair loss |
|---|---|---|---|
| Clascoterone | Androgen receptor | Topical | Investigational |
| Finasteride | DHT formation | Commonly oral | Established prescription option |
| Minoxidil | Follicle growth activity | Topical or clinician-prescribed oral use | Established options vary by formulation |
Cross-trial results are not direct comparisons. Studies can differ in participants, endpoints, duration and analysis.
How Is Clascoterone Different From Finasteride?
Clascoterone targets androgen receptors in treated skin. Finasteride reduces DHT formation and is commonly taken orally for male pattern hair loss.
A topical route does not automatically mean fewer risks, and clascoterone is not yet a proven finasteride replacement.
How Is Clascoterone Different From Minoxidil?
Minoxidil supports follicle activity through a non-anti-androgen pathway. Clascoterone targets androgen signaling, so the two should not be treated as interchangeable.
Potential combination use would need to follow evidence and any future approved label. Our oral minoxidil effectiveness and safety guide explains the considerations around systemic minoxidil.
Why There Is No Universal “Best” Option
Treatment choice depends on diagnosis, progression, medical history, priorities, tolerance for risk and ability to maintain the routine. We recommend waiting for complete evidence before making definitive clascoterone comparisons.
Clascoterone Side Effects and the Risks Still Unknown
“Topical” describes how a medicine is applied; it is not a safety guarantee. Public reporting has characterized the Phase 3 safety findings as favorable, but the available sources do not provide enough detail for precise event rates.
Known Adverse Events From the Studied Trials
Scalp or application-site reactions are relevant concerns with topical treatment, but their frequency and severity should be assessed from complete trial and regulatory documents.
Winlevi’s acne safety profile cannot simply be transferred to the scalp product because the formulation, concentration, dose and application area differ.
What “Low Systemic Exposure” Would and Would Not Mean
Any systemic-exposure finding applies to the dose, frequency, duration and participants studied. Lower exposure would not mean zero exposure or justify heavier use, application to damaged skin or use of unapproved formulations.
Questions Only Longer-Term and Real-World Evidence Can Answer
Open questions include rare adverse events, durability after stopping, use with other treatments, safety outside trial criteria and adherence in everyday life.
When Could Clascoterone for Hair Loss Become Available?
Available reporting indicates that a US regulatory filing is planned for early 2027. That is not an approval or launch date.
Filing Is Not Approval, and Approval Is Not Access
Regulators may request more data, alter labeling, delay a decision or decline approval. Approval would also not guarantee immediate supply, insurance coverage or affordability.
Can You Buy Clascoterone 5% Online?
An online listing cannot verify identity, purity, stability or equivalence to the trial formulation. We recommend against buying or self-using investigational clascoterone.
Who Might Fit the Studied Population—and Who May Need a Different Approach?
The reported trials involved men with mild-to-moderate androgenetic alopecia. Their findings do not automatically apply to women, advanced loss or other diagnoses.
Signs the Androgen Pathway May Be Relevant
Possible clues include gradual progression, temple or crown thinning, finer hairs in affected areas and a family history of patterned loss.
Signs Not to Assume This Is Pattern Hair Loss
Sudden shedding, sharply defined patches, pain, scaling, pustules, scarring or body-hair loss deserve clinical assessment. These features can point to conditions requiring a different approach.
Stop Guessing, Start With the Cause
A diagnosis-first review considers the pattern, onset, shedding, medications, health changes, scalp findings and relevant tests. Genetic insights can then add context.
The Practical Questions Headlines Leave Out
Future instructions must come from an approved label. Trial descriptions and forum routines are not personal dosing guidance.
A Treatment Only Works If the Routine Is Sustainable
A topical treatment must reach the scalp consistently. Drying time, residue, styling, washing, travel and refill access can all affect adherence.
Maintenance, Cost, and Refill Consistency
Pattern hair loss usually requires continued management. Clascoterone’s durability after stopping and its future cost should not be assumed before stronger evidence and launch details are available.
FAQ
Is Clascoterone a Hair-Loss Cure?
No. Reported hair-count improvement does not establish permanent regrowth or a cure.
Does Clascoterone Have Side Effects?
Adverse events are possible. Detailed trial data and regulatory review are needed to assess their frequency, severity and clinical importance.
Is Clascoterone Better Than Finasteride?
That has not been established. No suitable head-to-head evidence currently proves clascoterone is superior.
Is Triamcinolone Acetonide Cream Effective for Alopecia?
It may be used for selected inflammatory or autoimmune hair-loss conditions under clinical guidance. It is not a routine treatment for male pattern hair loss.
Is There Any Recent News About a Hair-Loss Cure?
There is promising treatment-development news, but no proof of a cure. Clascoterone remains investigational for hair loss.
Stop Guessing, Start Growing
Identify the cause before choosing a treatment. Explore personalized genetic hair-loss insights from Roots by GA and use them alongside an appropriate clinical assessment to build a more informed plan.
Roots by Genetic Arts
18 Nov 2026
Thanks for your order!
Login into your profile to set up your account.